Intellia Therapeutics Stock Analysis

Intellia Stock Analysis Notes

About 91.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.51. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Intellia Therapeutics recorded a loss per share of 5.45. The entity had not issued any dividends in recent years. Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. Intellia Thera operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 485 people. To find out more about Intellia Therapeutics contact Nessan Bermingham at 857 285 6200 or learn more at https://www.intelliatx.com.

Intellia Therapeutics Investment Alerts

Intellia Therapeutics Upcoming and Recent Events

Intellia Largest EPS Surprises

View All Earnings Estimates

Intellia Therapeutics Environmental, Social, and Governance (ESG) Scores

Intellia Stock Institutional Investors

Note, although Intellia Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Intellia Market Capitalization

The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.46 B.

Intellia Profitablity

Management Efficiency

Intellia Therapeutics has return on total asset (ROA) of (0.2781) % which means that it has lost $0.2781 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5223) %, meaning that it created substantial loss on money invested by shareholders. Intellia Therapeutics' management efficiency ratios could be used to measure how well Intellia Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of November 25, 2024, Return On Tangible Assets is expected to decline to -0.39. In addition to that, Return On Capital Employed is expected to decline to -0.46. At present, Intellia Therapeutics' Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 317.8 M, whereas Total Assets are forecasted to decline to about 686.6 M.

Technical Drivers

As of the 25th of November, Intellia Therapeutics retains the Market Risk Adjusted Performance of (0.21), standard deviation of 4.33, and Risk Adjusted Performance of (0.10). Concerning fundamental indicators, the technical analysis model lets you check existing technical drivers of Intellia Therapeutics, as well as the relationship between them.

Intellia Therapeutics Price Movement Analysis

Intellia Therapeutics Insider Trading Activities

Intellia Therapeutics Outstanding Bonds

Intellia Therapeutics Predictive Daily Indicators

Intellia Therapeutics Corporate Filings

Intellia Therapeutics Forecast Models

Intellia Therapeutics' time-series forecasting models are one of many Intellia Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Intellia Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Intellia Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Intellia shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Intellia Therapeutics. By using and applying Intellia Stock analysis, traders can create a robust methodology for identifying Intellia entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Intellia analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Intellia analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Intellia Therapeutics stock analysis indicators help investors evaluate how Intellia Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Intellia Therapeutics shares will generate the highest return on investment. By understating and applying Intellia Therapeutics stock analysis, traders can identify Intellia Therapeutics position entry and exit signals to maximize returns.

When running Intellia Therapeutics' price analysis, check to measure Intellia Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Intellia Therapeutics is operating at the current time. Most of Intellia Therapeutics' value examination focuses on studying past and present price action to predict the probability of Intellia Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Intellia Therapeutics' price. Additionally, you may evaluate how the addition of Intellia Therapeutics to your portfolios can decrease your overall portfolio volatility.